GENEVA, Switzerland, June 15, 2011 /PRNewswire/ -- BioXpress Therapeutics SA, a Swiss-based biotechnology company developing high-quality monoclonal antibody (MAb) biosimilars announced today representatives from the Company will be partnering at the 2011 BIO International Convention's One-on-One Partnering Meetings being held Jun 27-30 in Washington, D.C. at the Walter E. Washington Convention Center.
BioXpress Therapeutics currently has 4 biosimilar monoclonal antibody drugs in development with an additional 14 in the pipeline.
Representatives available to discuss partnering opportunities include: Dr. Cori Gorman and Dr. Curt Scribner. Companies or individuals attending BIO 2011 can schedule meetings with BioXpress Therapeutics by visiting (registration required): oneononepartnering.bio.org/BusinessForum2011/Login.aspx.
BioXpress Therapeutics Partnering Schedule:
Monday, June 27 Business Forum - 12:00 PM - 5:00 PM
Tuesday, June 28 Business Forum - 7:00 AM – 6:00 PM
Wednesday, June 29 Business Forum - 7:00 AM – 6:00 PM
Thursday, June 30 Business Forum - 7:00 AM – 6:00 PM
Each BioXpress Therapeutics biosimilar MAb is developed under strict non-clinical and clinical guidelines as outlined in the European Medicines Agency's "Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies." Furthermore, each BioXpress Therapeutics biosimilar goes through a complete analytical comparison to determine the product is similar to the innovator product.
Having the correct primary sequence is absolutely critical for a biosimilar to have similarity and comparability to the innovator drug. Typically, there are several sequences published for every marketed
|SOURCE BioXpress Therapeutics|
Copyright©2010 PR Newswire.
All rights reserved